This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Genexine, Inc.. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Mi Sun Byun: Innovator in Fusion Polypeptide Technology
Introduction
Mi Sun Byun is a prominent inventor based in Bucheon, South Korea. She has made significant contributions to the field of biotechnology, particularly in the development of fusion polypeptides. Her innovative work focuses on enhancing the efficacy of treatments for various medical conditions.
Latest Patents
Mi Sun Byun holds a patent for a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc. This invention is designed to improve the half-life and efficacy of the fusion polypeptide compared to conventional options. The patent addresses the need for effective treatments for diabetes, inflammatory bowel disease, endoenteritis, diarrhea caused by anticancer chemotherapy, and short bowel syndrome. The fusion polypeptide demonstrates increased resistance to the DPP-4 enzyme, leading to improved drug efficacy.
Career Highlights
Mi Sun Byun is currently employed at Genexine, Inc., where she continues to advance her research in biotechnology. Her work has positioned her as a key figure in the development of innovative therapeutic solutions.
Collaborations
Mi Sun Byun collaborates with notable colleagues, including Young Chul Sung and Se Hwan Yang. These partnerships enhance her research efforts and contribute to the advancement of her projects.
Conclusion
Mi Sun Byun's contributions to the field of fusion polypeptides represent a significant advancement in medical treatments. Her innovative approach and dedication to research continue to pave the way for improved healthcare solutions.